Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient.
Mortality in multiple sclerosis: meta-analysis of standardised mortality ratios.
The risk of smoking on multiple sclerosis: a meta-analysis based on 20,626 cases from case-control and cohort studies.
Comorbid Multiple Sclerosis and TDP-43 Proteinopathy in a Gulf War Sea Captain.
The effect of gabapentin on oxidative stress in a model of toxic demyelination in rat brain.
Change and processes of change within interventions to promote adjustment to multiple sclerosis: Learning from patient experiences.
Pathology and disease mechanisms in different stages of multiple sclerosis.
Integrin/Chemokine Receptor Interactions in the Pathogenesis of Experimental Autoimmune Encephalomyelitis.
Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis.
Fulminant Central Plus Peripheral Nervous System Demyelination without Antibodies to Neurofascin.
Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study.
Patients' experiences of adapting to multiple sclerosis: a qualitative study.
Biogen Idec to acquire full rights and control of Tysabri from Elan for upfront cash and contingent payments
Gray matter involvement in multiple sclerosis.
Merck KGaA Reaches Mutual Agreement with Ono Pharmaceutical to Terminate the License Agreement on Ceralifimod (ONO-4641)
Early phenotypic asymmetry of sister oligodendrocyte progenitor cells after mitosis and its modulation by aging and extrinsic factors.
Perceived impact of spasticity is associated with spatial and temporal parameters of gait in multiple sclerosis.
Increase in the prevalence of multiple sclerosis over a 17-year period in Osona, Catalonia, Spain.
CD200-CD200R1 interaction contributes to neuroprotective effects of anandamide on experimentally induced inflammation.
[Levels of Beclin 1 and LC3 in peripheral blood mononuclear cells of patients with multiple sclerosis and neuromyelitis optica and its significance].
The Implication of Vitamin D and Autoimmunity: a Comprehensive Review.
Impact of Clear, Loud and Slow Speech on Scaled Intelligibility and Speech Severity in Parkinson's Disease and Multiple Sclerosis.
[Neuromyelitis optica spectrum disorder: a case report].
Sarcoidosis Triggered by Interferon-Beta Treatment of Multiple Sclerosis: A Case Report and Focused Literature Review.
[HTLV-1-associated myelopathy/tropical spastic paraparesis : A differential diagnosis in multiple sclerosis.]
Pages
« first
‹ previous
…
210
211
212
213
214
215
216
217
218
…
next ›
last »